Ποια είναι η τιμή για Brainstorm Cell Therapeutics Inc. (BCLI)

Η τιμή για Brainstorm Cell Therapeutics Inc. (BCLI) είναι $1.10

Ποια είναι η κεφαλαιοποίηση αγοράς για Brainstorm Cell Therapeutics Inc. (BCLI)

Η κεφαλαιοποίηση αγοράς για Brainstorm Cell Therapeutics Inc. (BCLI) είναι $12.14M

Brainstorm Cell Therapeutics Inc. (BCLI) Τιμή και Κεφαλαιοποίηση Αγοράς

Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.

Η τιμή για BCLI	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$494,812 $12.14M	NVDA	$5.460T	+44,982,815.40%
$406,849 $12.14M	AAPL	$4.489T	+36,986,147.47%
$375,258 $12.14M	GOOG	$4.141T	+34,114,293.94%
$323,390 $12.14M	MSFT	$3.569T	+29,398,973.56%
$253,565 $12.14M	AMZN	$2.798T	+23,051,235.28%

Η τιμή για BCLI

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$494,812 $12.14M